Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rational therapeutic intervention in cancer: kinases as drug targets.

Current opinion in genetics & development - 1 Feb 2002

Sawyers Charles L

Abstract excerpt

Landmark clinical studies of new drugs developed to target specific forms of cancer were reported in 2001. Herceptin, a monoclonal antibody against the Her2/neu receptor tyrosine kinase, prolonged the survival of women with Her-2/neu positive metastatic breast cancer, when combined with chemotherapy. STI-571, a small molecule inhibitor of the Bcr-Abl, c-kit and platelet derived growth factor receptor tyrosine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antineoplastic Agents
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Delivery Systems

Share to Enzyme Inhibitors

Share to Neoplasms

Share to Protein-Tyrosine Kinases

Share to Receptor, ErbB-2

Source

Identifiers

PMID: 11790564
DOI: 10.1016/s0959-437x(01)00273-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rational therapeutic intervention in cancer: kinases as drug targets.PMID 11790564Read ↗

Kinase-targeted cancer therapies: progress, challenges and future directionsSemantic proximity Read ↗

Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors.Semantic proximity Read ↗

Receptor tyrosine kinases as targets for anticancer drugs.Semantic proximity Read ↗

Tyrosine kinases as targets for cancer therapy.Semantic proximity Read ↗

Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancerSemantic proximity Read ↗

Protein Kinases as Targets for Cancer TreatmentSemantic proximity Read ↗

Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous diseaseSemantic proximity Read ↗

Targeted Therapies in Cancer: To Be or Not to Be, SelectiveSemantic proximity Read ↗

[Kinase inhibitors].Semantic proximity Read ↗

Targeting tyrosine kinases in cancer: the second wave.Semantic proximity Read ↗

A New Challenging and Promising Era of Tyrosine Kinase InhibitorsSemantic proximity Read ↗

The molecular basis of targeting protein kinases in cancer therapeutics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.